Clients News • MC Services corporate website
paged,page-template-default,page,page-id-5522,paged-2,page-paged-2,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.3.0,vc_responsive




  • CENTOGENE GmbH: CENTOGENE Receives FDA Emergency Use Authorization for SARS-CoV-2 RT-PCR Assay for Individuals Without Symptoms or Other Reasons to Suspect COVID-19
  • Media Advisory: BIO-Europe® Digital | October 26–29, 2020 | European Standard Time
  • Topas Therapeutics Raises €22 Million (~USD 26 Million) in Series B Financing
  • Topas Therapeutics Appoints Klaus Martin, Ph.D. as Chief Executive Officer
  • CENTOGENE GmbH: Kooperation zwischen CENTOGENE und U-Diagnostics verstärkt COVID-19 Testkapazitäten in den Niederlanden
  • CENTOGENE GmbH: Collaboration Between CENTOGENE and U-Diagnostics Increases COVID-19 Testing Capacities in the Netherlands Information Security Management System Awarded ISO/IEC 27001:2017 Accreditation
  • Rentschler Biopharma SE: Rentschler Biopharma and ATUM announce Leap-In Transposase® licensing agreement for development of robust manufacturing processes for complex therapeutic proteins
  • France Biotech: HealthTech For Care and EIT Health Announce the Success of the HealthTech Innovation Days’ Second Edition
  • Apogenix Advances Clinical Development of CD95L Inhibitor Asunercept in European COVID-19 Phase II Trial
  • Verona Pharma plc: Verona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020